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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of PAE for the treatment of LUTS in men with BPH.
B A C K G R O U N D
Description of the condition
Benign prostatic hyperplasia (BPH) is histologically defined as
an increased number of epithelial and stromal cells in the peri-
urethral area of the prostate, whichmay cause prostate enlargement
(Roehrborn 2008). Prostate enlargement may constrict urine flow
and cause lower urinary tract symptoms (LUTS) (Dunphy 2015).
The development of LUTS resulting from BPH is associated with
increasing age, and most commonly encountered in men over the
age of 45 years (Barry 1997; Dunphy 2015; Egan 2016). LUTS
consist of storage symptoms (such as urinary frequency, urgency,
and nocturia) and voiding symptoms (such as urinary hesitancy,
weak urinary stream, straining to void, and prolonged voiding).
LUTS severity was positively correlated with men’s overall distress
using patient perception of bladder condition which can be mea-
sured by a single-item global question (ranging from 1 (causes no
problems at all) to 6 (causes severe problems)) (Chapple 2017).
However, LUTS are relatively unspecific and may also be asso-
ciated with bladder disorders, such as detrusor overactivity. The
focus of this review specifically considers the term BPH as pro-
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static enlargement with LUTS through which to define the dis-
ease condition and potential need for intervention (Dunphy 2015;
Roehrborn 2008).
The histological prevalence of BPH is reported to be 8% in the
fourth decade of life, and up to 40% and 70% in the sixth and
eighth decade of life, respectively (Barry 1995; Roehrborn 2008;
Yoo 2012). Aside from LUTS, untreated BPH can result in other
serious medical consequences, such as acute urinary retention, uri-
nary tract infection, and upper urinary tract deterioration. Sub-
sequently, BPH results in a negative impact on public health and
a reduction in a person’s quality of life (Martin 2014; Yoo 2012).
BPH results in a significant economic burden as well, with an es-
timated cost to the USA of USD 4 billion (Taub 2006). It is rea-
sonable to assume that the cost will escalate further in the future
with the increasing rise in the male population over 65 years of
age (Centers for Disease Control and Prevention 2003).
Treatment decisions in patients with BPH are typically based on
the severity of symptoms and subjectively perceived bother, pres-
ence of complications, such as acute urinary retention, risk of
progression, and treatment-related morbidity. Self-administered
questionnaires, namely the International Prostate Symptom Score
(IPSS) which consists of eight questions (seven symptomquestions
+ one quality of life question) to evaluate the symptom severity
and relative degree of bother, have been used to guide the manage-
ment of the LUTS (Barry 1995).Watchful waiting and behavioral
management are an appropriate first-line option in patients with
mild or non-bothersome symptoms. Additionalmedical treatment
options in patients with more bothersome symptoms consist of
alpha-blockers, 5-alpha reductase inhibitors or the combination
of these two kinds of drugs (EAU 2017; McVary 2011). If conser-
vative and medical treatment fail or BPH-related complications,
such as acute urinary retention, recurrent urinary tract infection,
bladder stones, hematuria, or renal insufficiency occur, surgical
options are considered (EAU 2017; McVary 2011).
There are a wide variety of surgical options for the treatment of
BPH, fromopen simple prostatectomy tominimally invasive surg-
eries, such as transurethral resection of the prostate (TURP), laser
ablation or enucleation of the prostate. According to the current
guidelines, TURP remains the “gold standard” surgical procedure
for men over 40 years of age who seek professional help for various
forms of non-neurogenic benign forms of LUTS. While TURP
resulted in a mean decrease in LUTS of 70.0% and a mean in-
crease in maximum flow rate (Qmax) by 162%, considerable rates
of perioperative and long-term complications, such as bleeding re-
quiring blood transfusion (2%), transurethral resection syndrome
(0.8%), acute urinary retention (4.5%), clot retention (4.9%), uri-
nary tract infection (4.1%), bladder neck stenosis (4.7%), urethral
stricture (3.8%), retrograde ejaculation (65.4%), and erectile dys-
function (6.5%), have been reported (Ahyai 2010). TURP also
commonly requires a period of temporary catheterization, or hos-
pital admission, or both. Reducing treatment-related morbidity
and patient burden have therefore motivated the development of
new, minimally invasive alternatives.Minimally invasive surgeries,
such as those using electrode, laser, transurethral thermal abla-
tion of prostate (needle ablation, microwave therapy, and radiofre-
quency ablative techniques), and mechanical stents have been in-
troduced and are widely recognized as alternatives to TURP for
some patients (EAU 2017; McVary 2011). Prostatic arterial em-
bolization (PAE) represents a relatively new, minimally invasive
treatment option, particularly suitable for men who are at high
risk of anesthesia (Wang 2015).
Description of the intervention
Embolization of the prostatic arteries has historically been used
to control persistent or massive prostatic bleeding that cannot
otherwise be controlled, with typical causes being BPH, locally
advanced prostate cancer, or after transurethral prostatectomy
(Mitchell 1976). DeMeritt 2000 reported a case of performing
PAE with polyvinyl alcohol particles for BPH induced hematuria
in which the hematuria immediately stopped and the patient also
had symptomatic improvement of his BPH symptoms. They also
found that his prostate size was reduced to 52% and 62% of the
initial size at five and 12 month follow-up, respectively. Carnevale
2010 reported positive preliminary results of PAE procedures with
microspheres as a primary treatment in two patients with acute
urinary retention due to BPH. For elderly symptomatic BPH pa-
tients, PAE has been introduced as an alternative treatment ap-
proach that is performed by a femoral artery puncture using con-
scious sedation instead of general anesthesia. The procedure is
typically performed on an outpatient basis and usually does not
require catheterization, unless the patient is in urinary retention
beforehand (Wang 2015).
Prior to PAE, preoperative computed tomography or magnetic
resonance angiography is typically performed to enable the evalua-
tion of the pelvic artery anatomy. Digital subtraction angiography
of the right and left internal iliac arteries is performed to assess
the prostatic blood supply (Martins Pisco 2012). Super selective
microcatheterization and embolization are then performed on the
prostatic arteries. Embolization is typically performed to complete
stasis (Carnevale 2010; Martins Pisco 2012; Wang 2015). Cone
beam computed tomography can be used to not only help identify
all prostatic arteries, but to also identify and avoid the embolization
of vessels feeding adjacent pelvic structures (Wang 2015). Particle
embolics are almost exclusively used, however, the type and size
of particles has varied widely (Carnevale 2010; DeMeritt 2000).
The use of vasodilatory medications, once the prostatic artery is
catheterized, is also recommended by some authors to avoid pre-
mature stasis due to arterial spasm (Martins Pisco 2012).
Adverse effects of the intervention
Themajor complications of PAEwere perineal pain (9.4%), hema-
turia (9%), and acute urinary retention (7%) (Feng 2017). Acute
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urinary retention was the common adverse event in PAE when
compared to the control group (9.4% versus 2.0%). The high-
est prevalence of acute urinary retention was 28.4% amongst
the included studies (Wang 2015). Minor complications, such as
hematospermia, rectal bleeding, urinary tract infection, inguinal
hematoma, and transient urinary frequency were also reported
(Feng 2017; Kuang 2017; Pyo 2017; Shim 2017).
How the intervention might work
The underlyingmechanism of PAE is the ischemia or hypoxia that
induces apoptosis, necrosis, sclerosis, and prostatic shrinkage with
cystic transformation of part, or all of the gland, resulting in a
softer gland with reduced compression of the urethra (DeMeritt
2000; Sun 2008). In addition, PAE may decrease the plasma con-
centration of free testosterone that enters prostate cells, thereby
lowering the dihydrotestosterone levels in the prostate. This may
result in the secondary inhibition of prostate growth (Sun 2008).
Furthermore, ischemia or hypoxia may induce prostate cell death
and necrosis with a decreased number of some receptors, such as al-
pha-adrenergic receptors. Therefore, the neuromuscular tone may
decrease and result in an improvement in clinical symptoms asso-
ciated with the dynamic pathologic component of BPH (Zlotta
1997).
Why it is important to do this review
Despite reported relative advantages of PAE, it remains unclear
how this procedure compares to the numerous surgical alterna-
tives that exist. While there are existing systematic reviews that
compare PAE to other therapies used to treat BPH (Feng 2017;
Kuang 2017; Pyo 2017; Shim 2017), none so far has used the
same rigorous methodology as Cochrane Reviews, which includes
the application of the GRADE approach and its focus on patient-
important outcomes (Guyatt 2008). In this era, with the avail-
ability of numerous minimally invasive procedures to treat LUTS
suggestive of BPH, the findings of this Cochrane Review will be
relevant to policymakers, healthcare providers and patients alike.
O B J E C T I V E S
To assess the effects of PAE for the treatment of LUTS in men
with BPH.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include parallel group randomized controlled trials (RCTs)
and cluster-RCTs. We will exclude cross-over trials, as these study
designs are not relevant in this setting. If we only find RCTs that
provide low-quality evidence for a given outcome and compar-
ison, we will also include non-RCTs, such as cohort and cross-
sectional studies with concurrent comparison groups, as a source
of complementary, sequential or replacement evidence for RCTs
(Schunemann 2013a). We will not consider including single-
armed studies. We will include studies regardless of their publica-
tion status or language of publication.
Types of participants
We will define the eligible patient population as men over the age
of 40 with a minimum prostate volume of 20 mL or greater (as
assessed by ultrasound or cross-sectional imaging), with LUTS as
determined by an IPSS of eight or over, and a Qmax of less than
15 mL/sec, as measured by non-invasive uroflowmetry, or invasive
pressure flow studies, or both (EAU 2017; McVary 2011). The
age limitation is based on the observation that the prevalence of
BPH increases in middle-aged and older men, and is infrequent
in younger men (Barry 1997; EAU 2017; Egan 2016). We will
include studies in which only a subset of participants are relevant
to this review, if data are available separately for the relevant subset.
We will exclude trials of men with chronic renal failure, untreated
bladder calculi or large diverticula, a diagnosis of prostate cancer,
urethral stricture disease, and prior prostate, bladder neck, or ure-
thral surgery. We will also exclude studies of patients with other
conditions that affect urinary symptoms, such as neurogenic blad-
der due to spinal cord injury, multiple sclerosis, or central nervous
system disease.
Types of interventions
We plan to investigate the following comparisons of experimental
intervention versus comparator interventions. Concomitant inter-
ventions will have to be the same in the experimental and com-




• Sham control (or no intervention)
• TURP (monopolar or bipolar)
• Laser ablations of the prostate (e.g. photoselective
vaporization of the prostate)
• Laser enucleations of the prostate (e.g. holmium laser
enucleation of the prostate)
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• Other minimally invasive therapies (e.g. transurethral
incision of the prostate, transurethral thermal ablation of the
prostate (needle ablation, microwave therapy, and radiofrequency
ablative techniques), prostate stent, and prostatic urethral lift)
Comparisons
• PAE versus sham control (or no intervention)
• PAE versus TURP
• PAE versus laser ablations of the prostate
• PAE versus laser enucleations of the prostate
• PAE versus other minimally invasive therapies
Types of outcome measures
We will not use the measurement of the outcomes assessed in this
review as an eligibility criterion.
Primary outcomes
• Urologic symptom scores
• Quality of life





• Minor adverse events
• Acute urinary retention
• Indwelling urinary catheter
• Hospital stay
Method and timing of outcome measurement
Wewill use clinically important difference for the review outcomes
to rate overall quality of the evidence in the ’Summary of findings’
table (Johnston 2010).
Urologic symptom scores
• Mean change measured as a validated scale (such as IPSS).
• We will consider improvement of the IPSS score of three
points as a minimal clinically important difference (MCID) to
assess efficacy and comparative effectiveness (Barry 1995). If
possible, we will use different thresholds of MCID based on the
severity of IPSS with a threshold of three for men with mild
LUTS, five for moderate LUTS, and eight for severe LUTS
(Barry 1995).
Quality of life
• Mean change measured as a validated scale (such as IPSS-
quality of life or BPH Impact Index).
• No threshold was established for the IPSS-quality of life.
We will use a MCID of one to assess efficacy and comparative
effectiveness (Brasure 2016). We will consider improvement of
the BPH Impact Index score of 0.5 as a MCID (Barry 1995).
Major adverse events
• For example, postoperative hemorrhage requiring
admission or intervention.
• We will use the Clavien-Dindo classification system to
assess surgical complications (Dindo 2004), and will categorize
grade III, IV and V complications as major. If the study authors
of eligible studies did not use the Clavien-Dindo system, we will
judge the adverse events by severity using the available
information described in the studies.
Retreatment
• Events requiring other surgical treatment modalities (e.g.
TURP) within at least six months follow-up due to treatment
failure after intervention.
Erectile function
• Mean change, measured as erectile function domain of
International Index of Erectile Function (IIEF) or total score of
IIEF-5 questionnaire (Rosen 1997).
• We will consider the MCID in the erectile function domain
score of IIEF of four (Rosen 2011). If possible, we will use
different thresholds of MCID based on the severity of ED, with
a threshold of two for men with mild erectile dysfunction, five
for moderate erectile dysfunction, and seven for men with severe
erectile dysfunction (Rosen 2011). We will also consider
improvement of IIEF-5 of over five points as MCID (Spaliviero
2010).
Ejaculatory function
• Mean change, measured as Male Sexual Health
Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD; Rosen
2007).
Minor adverse events
• For example, postoperative fever or pain requiring
medication.
• We will use the Clavien-Dindo classification system to
assess surgical complications (Dindo 2004), and will categorize
grade I and II complications as minor. If the authors did not use
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the Clavien-Dindo system, we will grade the adverse events as
described above.
Acute urinary retention
• Events requiring catheterization after intervention.
Indwelling urinary catheter
• Measured in days from intervention to urinary catheter
removal.
Hospital stay
• Measured in days from admission to discharge.
There is no reported threshold in adverse events, retreatment,
ejaculatory function, acute urinary retention, indwelling urinary
catheter, and hospital stay. We will consider the clinically im-
portant difference for adverse events, retreatment, and acute uri-
nary retention as a relative risk reduction of at least 25% (Guyatt
2011a). We will use a MCID of 25% improvement from baseline
in MSHQ-EjD for ejaculatory function (Nickel 2015). We will
use a clinically important difference of one day to assess efficacy
and comparative effectiveness for indwelling urinary catheter and
hospital stay.
We will consider outcomes measured up to and including 12
months after randomization as short-term and later than 12
months as long-term for urologic symptom scores, quality of life,
major adverse events, erectile function, ejaculatory function, mi-
nor adverse events, and acute urinary retention. We assessed re-
treatment, indwelling urinary catheter and hospital stay as short-
term only.
Main outcomes for ’Summary of findings’ table
We will present a ’Summary of findings’ table reporting the fol-
lowing outcomes listed according to priority.
1. Urologic symptom scores.
2. Quality of life.




Search methods for identification of studies
We will perform a comprehensive search, with no restrictions on
the language of publication or publication status.We plan to rerun
searches within three months prior to anticipated publication of
the review.
Electronic searches
We will search the following sources from inception of each
database.
• Cochrane Library via Wiley (Appendix 1).
◦ Cochrane Database of Systematic Reviews (CDSR).
◦ Cochrane Central Register of Controlled Trials
(CENTRAL).
◦ Database of Abstracts of Reviews of Effects (DARE).
◦ Health Technology Assessment Database (HTA).
• MEDLINE via Ovid (from 1946; Appendix 2).
• EMBASE via Ovid (from 1974; Appendix 3).
• Scopus (from 1966).
• Web of Science (from 1900).
• Google Scholar.
We will also search the following.
• ClinicalTrials.gov (www.clinicaltrials.gov/).
• World Health Organization (WHO) International Clinical
Trials Registry Platform search portal (apps.who.int/trialsearch/).
• Grey literature repository from the current Grey Literature
Report (www.greylit.org/).
If we detect additional relevant key words during any of the elec-
tronic or other searches, wewill modify the electronic search strate-
gies to incorporate these terms and document the changes.
Searching other resources
We will try to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, reviews, meta-analyses and health technology assessment re-
ports. We will also contact study authors of included trials to iden-
tify any further studies that we may have missed. We will contact
drug/device manufacturers for ongoing or unpublished trials. We
will search for unpublished studies by handsearching the abstract
proceedings of the annual meetings of the American Urological
Association, European Association of Urology, and Radiological
Society of North America for the last three years (2015 to 2017).
Data collection and analysis
Selection of studies
Wewill use referencemanagement software to identify and remove
potential duplicate records (EndNote 2016). Two review authors
(JHJ, KAM, VN or BR) will independently scan the abstract, ti-
tle, or both, of remaining records retrieved, to determine which
studies should be assessed further through Covidence 2017. Two
review authors (JHJ, KAM, VN, or BR) will investigate all poten-
tially relevant records as full text, map records to studies, and clas-
sify studies as included studies, excluded studies, studies awaiting
classification, or ongoing studies, in accordance with the criteria
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for each provided in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). We will resolve any discrepan-
cies through consensus or recourse to a third review author (PD).
If resolution of a disagreement is not possible, we will designate
the study as ’awaiting classification’ and we will contact study au-
thors for clarification. We will document reasons for exclusion of
studies that may have reasonably been expected to be included in
the review in a ’Characteristics of excluded studies’ table. We will
present an adapted PRISMA flow diagram showing the process of
study selection (Liberati 2009).
Data extraction and management
We will develop a dedicated data abstraction form that we will
pilot test ahead of time.
For studies that fulfil inclusion criteria, two review authors (JHJ,
KAM,VN, or BR)will independently abstract the following infor-
mation, which we will provide in the ’Characteristics of included
studies’ table.
• Study design.
• Study dates (if dates are not available then this will be
reported as such).
• Study settings and country.
• Participant inclusion and exclusion criteria (e.g. age,
baseline IPSS).
• Participant details, baseline demographics (e.g. age, prostate
size, IPSS, American Society of Anesthesiologists physical status
classification system, radiation dose for PAE).
• The number of participants by study and by study arm.
• Details of relevant experimental and comparator
interventions, such as embolization catheterization approach
(unilateral or bilateral) and characteristics of the embolization
agent used (e.g. polyvinyl alcohol particle size).
• Definitions of relevant outcomes, and method (e.g. type of
instrument, such as IPSS) and timing of outcome measurement
(e.g. in months) as well as any relevant subgroups (e.g. based on
age, prostate volume, severity of LUTS).
• Study funding sources.
• Declarations of interest by primary investigators.
We will extract outcome data relevant to this Cochrane Review
as needed for calculation of summary statistics and measures of
variance. For dichotomous outcomes, we will attempt to obtain
numbers of events and totals for population of a 2x2 table, as well
as summary statistics with corresponding measures of variance.
For continuous outcomes, we will attempt to obtain means and
standard deviations or data necessary to calculate this information.
We will resolve any disagreements by discussion, or, if required,
by consultation with a third review author (PD).
We will provide information, including trial identifier, about po-
tentially relevant ongoing studies in the table ’Characteristics of
ongoing studies’.
We will attempt to contact authors of included studies to obtain
key missing data as needed.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary study, we will maximize yield of
information by mapping all publications to unique studies and
collating all available data. We will use the most complete data
set aggregated across all known publications. In case of doubt, we
will give priority to the publication reporting the longest follow-
up associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two review authors (JHJ, KAM, VN, or BR) will assess the risk
of bias of each included study independently. We will resolve dis-
agreements by consensus, or by consultation with a third review
author (PD). We will present a ’Risk of bias’ summary figure to
illustrate these findings. We will further summarize the risk of bias
across domains for each outcome in each included study, as well as
across studies and domains for each outcome in accordance with
the approach for summary assessments of the risk of bias presented
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b; Sterne 2016). We will not combine risk of bias
from RCTs with that from non-RCTs due to inherently different
biases between each study design (Reeves 2011).
Assessment of risk of bias in RCTs
Wewill assess risk of bias usingCochrane’s ’Risk of bias’ assessment
tool (Higgins 2011b). We will assess the following domains.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other sources of bias.
We will judge risk of bias domains as ’low risk’, ’high risk’ or
’unclear risk’ and will evaluate individual bias items as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011b).
For selection bias (random sequence generation and allocation
concealment), we will evaluate risk of bias at a trial level.
For performance bias (blinding of participants and personnel), we
will consider all outcomes similarly susceptible to performance
bias.
For detection bias (blinding of outcome assessment), wewill group
outcomes as susceptible to detection bias (subjective outcomes) or
not susceptible to detection bias (objective outcomes).
We define the following endpoints as subjective outcomes.
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• Urologic symptom scores.
• Quality of life.
• Major adverse events.
• Erectile function.
• Ejaculatory function.
• Minor adverse events.
We define the following endpoints as objective outcomes.
• Retreatment.
• Acute urinary retention.
• Indwelling urinary catheter.
• Hospital stay.
We will assess attrition bias (incomplete outcome data) on a per
outcome basis, but will seek to create groups of outcomes based
on similar reporting characteristics.
For reporting bias (selective reporting), we will evaluate risk of bias
at a trial level.
We will further summarize the risk of bias across domains for
each outcome in each included study, as well as across studies and
domains for each outcome, in accordance with the approach for
summary assessments of the risk of bias presented in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011b).
Assessment of risk of bias in non-RCTs
We will assess risk of bias in non-RCTs with ROBINS-I: a tool for
assessing risk of bias in non-randomised studies of interventions
(Sterne 2016). We will assess the following domains.
• Bias due to confounding.
• Bias in selection of participants into the study.
• Bias in classification of interventions.
• Bias due to deviations from intended interventions.
• Bias due to missing data.
• Bias in measurement of outcomes.
• Bias in selection of the reported result.
We will judge risk of bias domains as ’low risk’, ’moderate risk’,
’serious risk’, ’critical risk’, or ’no information’ and will evaluate
individual bias items as described in Sterne 2016.
Measures of treatment effect
We will express dichotomous data as risk ratios with 95% con-
fidence intervals (CIs). We will express continuous data as mean
differences (MDs) with 95% CIs unless different studies use dif-
ferent measures to assess the same outcome, in which case we will
express data as standardized MDs with 95% CIs.
Unit of analysis issues
The unit of analysis will be the individual participant. Should we
identify cluster-randomized trials, or trials with more than two in-
tervention groups for inclusion in the review, we will handle these
in accordance with guidance provided in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011c).
Dealing with missing data
We will obtain missing data from study authors, if feasible, and
will perform intention-to-treat analyses if data are available; we
will otherwise perform available case analyses. We will investigate
attrition rates, e.g. dropouts, losses to follow-up and withdrawals,
and will critically appraise issues of missing data. We will not
impute missing data.
Assessment of heterogeneity
In the event of excessive heterogeneity, unexplained by subgroup
analyses, we will not report outcome results as the pooled effect
estimate in ameta-analysis. but will provide a narrative description
of the results of each study.
We will identify heterogeneity (inconsistency) through visual in-
spection of the forest plots to assess the amount of overlap of CIs,
and the I2 statistic, which quantifies inconsistency across studies
to assess the impact of heterogeneity in the meta-analysis (Higgins
2002; Higgins 2003); we will interpret the I2 statistic as follows
(Deeks 2011).
• 0% to 40%: may not be important.
• 30% to 60%: may indicate moderate heterogeneity.
• 50% to 90%: may indicate substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
When we find heterogeneity, we will attempt to determine pos-
sible reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
We will attempt to obtain study protocols to assess for selective
outcome reporting.
If we include 10 studies or more investigating a particular out-
come, we will use funnel plots to assess small study effects. Several
explanations can be offered for the asymmetry of a funnel plot,
including true heterogeneity of effect with respect to trial size,
poor methodological design (and hence bias of small trials) and
publication bias. We will therefore interpret results carefully.
Data synthesis
Unless there is good evidence for homogeneous effects across stud-
ies, we will summarize data using a random-effects model. We
will interpret random-effects meta-analyses with due considera-
tion of the whole distribution of effects. In addition, we will per-
form statistical analyses according to the statistical guidelines con-
tained in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011a). For dichotomous outcomes, we will use
7Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the Mantel-Haenszel method; for continuous outcomes, we will
use the inverse variance method. We will use Review Manager 5
software to perform analyses (Review Manager 2014).
We will analyze the results for RCTs and non-RCTs separately
(Reeves 2011).
Subgroup analysis and investigation of heterogeneity
We expect the following characteristics to introduce clinical het-
erogeneity, and plan to carry out subgroup analyses with investi-
gation of interactions.
• Patient age (less than 65 years versus greater than or equal
to 65 years).
• Prostate volume (less than or equal to 40 mL versus greater
than 40 mL).
• Severity of LUTS based on IPSS (score less than or equal to
19 (moderately symptomatic) versus greater than 19 (severely
symptomatic)).
These subgroup analyses are based on the following observations.
• Age is a well-known risk factor of BPH surgery. Elderly
patients have a higher rate of postoperative complications
compared with younger patients (Bhojani 2014; Pariser 2015).
The age cut-off is based on the WHO definition of old age
(WHO 2002).
• The outcomes and complications of ablative procedures,
such as TURP correlate with prostate volume (Reich 2008). The
prostate volume cut-off > 40 cc is based on this being the most
commonly used threshold to distinguish ’small’ from ’large’ for
the indication of treatment with a 5-alpha reductase inhibitor
(EAU 2017).
• The relationship between changes in IPSS scores and
patient global ratings of improvement is influenced by the
baseline scores (Barry 1995).
We plan to perform subgroup analyses limited to the primary
outcomes. We will use the test for subgroup differences in Review
Manager 2014 to compare subgroup analyses if there are sufficient
studies.
Sensitivity analysis
We plan to perform sensitivity analyses limited to the primary
outcomes in order to explore the influence of the following factor
(when applicable) on effect sizes.
• Restricting the analysis by taking into account risk of bias,
by excluding studies at ’high risk’ or ’unclear risk’.
’Summary of findings’ table
Wewill present the overall quality of the evidence for each outcome
according to the GRADE approach, which takes into account five
criteria not only related to internal validity (risk of bias, incon-
sistency, imprecision, and publication bias), but also to external
validity, such as directness of results (Guyatt 2008). For each com-
parison, two review authors (JHJ, KAM, VN, or BR) will inde-
pendently rate the quality of evidence for each outcome as ’high’,
’moderate’, ’low’, or ’very low’ using GRADEpro GDT 2015. We
will resolve any discrepancies by consensus, or, if needed, by arbi-
tration by a third review author (PD). For each comparison, we
will present a summary of the evidence for the main outcomes
in a ’Summary of findings’ table, which provides key information
about the best estimate of the magnitude of the effect in relative
terms and absolute differences for each relevant comparison of
alternative management strategies; numbers of participants and
studies addressing each important outcome; and the rating of the
overall confidence in effect estimates for each outcome (Guyatt
2011b; Schünemann 2011b). If meta-analysis is not possible, we
will present results in a narrative ’Summary of findings’ table.
For RCTs, we will take into account five criteria not only related
to internal validity (risk of bias, inconsistency, imprecision, and
publication bias), but also to external validity, such as directness
of results for downgrading the quality of evidence for a specific
outcome (Schünemann 2011c). For non-RCTs, we will take into
account three criteria for upgrading the quality of evidence (large
magnitude of effects, all plausible confounding that would reduce
a demonstrated effect or suggest a spurious effect when results
showno effect, and dose-response gradient) (Schünemann 2011c).
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A P P E N D I C E S
Appendix 1. Cochrane Library search strategy
1 MeSH descriptor: [Prostatic Hyperplasia] explode all trees
2 (hyperplasia near/3 prostat*):ti,ab,kw (Word variations have been searched)
3 hyperplasia of the prostate:ti,ab,kw (Word variations have been searched)
4 prostatic hyperplasia:ti,ab,kw (Word variations have been searched)
5 (hypertrophy near/3 prostat*):ti,ab,kw (Word variations have been searched)
6 (adenoma* near/3 prostat*):ti,ab,kw (Word variations have been searched)
7 MeSH descriptor: [Lower Urinary Tract Symptoms] explode all trees
8 lower urinary tract or “luts”:ti,ab,kw (Word variations have been searched)
9 prostatism:ti,ab,kw (Word variations have been searched)
10 MeSH descriptor: [Prostatism] explode all trees
11 MeSH descriptor: [Urinary Bladder Neck Obstruction] explode all trees
12 bladder outlet obstruction:ti,ab,kw (Word variations have been searched)
13 (prostat* near/3 enlarg*):ti,ab,kw (Word variations have been searched)
14 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13
15 MeSH descriptor: [Embolization, Therapeutic] explode all trees
16 emboli?ation*:ti,ab,kw (Word variations have been searched)
17 15 OR 16
18 14 AND 17
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Appendix 2. MEDLINE (via Ovid) search strategy
1 exp Prostatic Hyperplasia/
2 Prostat* adj3 hyperplasia.tw.
3 Prostat* adj3 adenoma.tw.
4 Prostat* adj3 hypertrophy.tw.
5 (BPH or BPO or BPE).tw.
6 exp Lower Urinary Tract Symptoms/




11 exp Urinary Bladder Neck Obstruction/
12 (Bladder* adj3 obstruct*).tw.
13 BOO.tw.
14 1-13 OR
15 exp Embolization, Therapeutic/
16 emboli#ation$.tw.
17 15-16 OR
18 14 AND 17
19 (animals not (humans and animals)).sh.
20 18 not 19
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Appendix 3. EMBASE (via Ovid) search strategy
1 prostate hypertrophy’/exp
2 hyper* NEAR/3 prostat*):ab,ti
3 (adenoma* NEAR/3 prostat*):ab,ti
4 BPH’ OR ’BPO’ OR ’BPE’:ab,ti
5 lower urinary tract symptom’/exp




10 (bladder* NEAR/3 obstruct*) OR ’BOO’ :ab,ti
11 (prostat* NEAR/3 (enlarg* OR obstruct*)):ab,ti
12 ((urinary or urethra* or urination or LUT*) NEAR/3 (symptom* or complain*)):ab,ti




17 14 OR 15
18 13 AND 16
19 (’animals’/exp) NOT (’humans’/exp and ’animals’/exp)
20 17 not 18
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